Earnings Presentation
Financial Results for Q4 FY2025

May 12, 2026

FUJIFILM Holdings Corporation

Forward-looking statements, such as those relating to earnings forecasts and other projections contained in this material, are management's current assumptions and beliefs based on currently available information. Such forward-looking statements are subject to a number of risks, uncertainties, and other factors. Accordingly, actual results may differ materially from those projected due to various factors.

FUJIFILM
Value from Innovation

Consolidated Financial Results for Q4 FY2025 (January to March 2026)

1 **Earnings Highlights and VISION2030 Progress**
Teiichi Goto, President, Representative Director & CEO
FUJIFILM Holdings Corporation

2 **Financial Results and Business Summary by Operating Segment**
Masayuki Higuchi, Director & Corporate Vice President, CFO
FUJIFILM Holdings Corporation

FY2026 (Fiscal Year Ending March 2027)

3 **Financial Forecast for FY2026**
Masayuki Higuchi, Director & Corporate Vice President, CFO
FUJIFILM Holdings Corporation

FY2025
Earnings Highlights and VISION2030 Progress

01

Earnings Highlights for FY2025

Consolidated Performance for FY2025

(Exchange rates: ¥151/US$ | -¥1 YoY; ¥175/Euro | +¥11 YoY)

Revenue

Record high

¥3,357.0 billion

Change from previous year (⬆ +5.0%)

Operating income

Record high

¥350.2 billion

(⬆ +6.1%)

Net income attributable to FUJIFILM Holdings

Record high

¥276.7 billion

(⬆ +6.0%)

- Revenue, operating income and net income attributable to FUJIFILM Holdings all posted record highs
- Revenue increased, driven by the Healthcare segment, in which the launch of new Bio CDMO facilities in Denmark contributed to growth, as well as the Electronics segment, which recorded strong sales of Semiconductor Materials, including CMP slurries, and the Imaging segment, in which digital cameras and other products posted robust sales
- Despite additional U.S. tariffs and higher raw material costs, operating income increased mainly due to an improvement in gross margin driven by revenue growth

Consolidated Performance for Q4 FY2025

(Exchange rates: ¥157/US$ | +¥5 YoY; ¥184/Euro | +¥23 YoY)

Revenue

Record high

¥927.3 billion

Change from previous year (⬆ +6.8%)

Operating income

¥101.8 billion

(⬇ -4.8%)

Net income attributable to FUJIFILM Holdings

Record high

¥83.4 billion

(⬆ +5.0%)

- Revenue and net income attributable to FUJIFILM Holdings all posted record highs for the fourth quarter

Highlights of Financial Forecast for FY2026

Full-year Forecast for FY2026

(Exchange rates for FY2026: ¥150/US$ |-¥1 YOY; ¥175/Euro | YoY unchanged)

Revenue

Record high

¥ 3,470.0 billion

Change from FY2025 ⬆ +3.4%

Operating income

Record high

¥ 365.0 billion

⬆ +4.2%

Net income
attributable to FUJIFILM Holdings

Record high

¥ 280.0 billion

⬆ +1.2%

Points

⚠ **The potential impact of fluctuations in raw material prices and energy costs due to heightened tensions in the Middle East has not been factored into the above financial forecast for FY2026, due to significant uncertainty regarding future conditions.** Refer to p. 20 for details.

- Aiming for record high revenue, driven by the expansion of operations at new large-scale Bio CDMO manufacturing facilities and increased sales of Semiconductor Materials
- Also aiming to **achieve record highs** in operating income and net income attributable to FUJIFILM Holdings, supported by the strong performance of the Electronics and Imaging, together with concerted pricing measures across all businesses to offset rising raw materials costs, including semiconductor memory and silver (see the next page for progress against the medium-term management plan)
- Annual dividend is planned at ¥75.0 per share, **marking the 17th consecutive annual increase**

Highlights of Financial Forecast for FY2026: VISION2030 Progress


- **Aiming to achieve the targets for revenue, operating income and net income attributable to FUJIFILM Holdings as set forth in the medium-term management plan (VISION2030)**
- **Aiming to improve ROE and ROIC by enhancing profitability through the launch of new large-scale Bio CDMO manufacturing facilities, thereby improving capital efficiency**

	FY2025 Results	FY2026 Forecast	Change from FY2025	(Reference) FY2026 VISION2030
Revenue	¥3,357.0 billion	Record high **¥3,470.0 billion**	+ 3.4 %	¥3,450.0 billion
Operating Income	¥350.2 billion	Record high **¥365.0 billion**	+ 4.2 %	¥360.0 billion
Operating Margin	10.4 %	**10.5 %**	+ 0.1 %	10.4 %
Net Income Attributable to FUJIFILM Holdings	¥276.7 billion	Record high **¥280.0 billion**	+ 1.2 %	¥270.0 billion
ROE	7.7 %	**7.8 %**	+ 0.1 pt	8.1 %
ROIC	5.5 %	**5.6 %**	+ 0.1 pt	5.8 %
Exchange rate ¥/US$	¥151	**¥150**	(¥1)	¥140
¥/€	¥175	**¥175**	-	¥150

Shareholder Returns

- **The annual dividend for FY2025 is planned at ¥70.0 per share**
- **On March 30, 2026, the Company announced a share buyback of up to ¥30.0 billion and the cancellation of all shares repurchased. The share buyback was completed on April 30**
- **The annual dividend for FY2026 is planned at ¥ 75.0 per share (up ¥5.0 YoY), marking the 17th consecutive annual increase**





02

FY2025
Financial Results and Business Summary by Operating Segment

* From Q2 FY2024, the amounts shown for each item in this document have been rounded off to the nearest ¥100 million. As a result, there may be some discrepancies from figures published in the past, and in some cases there may be differences between the breakdown and the total. Percentages are based on the actual amount.

Financial Results for FY2025

(Billions of yen)

	Q4				Full Year			
	FY2024	FY2025	Change	Excluding FX, one-time cost and raw material impacts	FY2024	FY2025	Change	Excluding FX, one-time cost and raw material impacts
Revenue	868.3 100.0%	Record high 927.3 100.0%	58.9 +6.8%	26.8 +3.1%	3,195.8 100.0%	Record high 3,357.0 100.0%	161.1 +5.0%	144.2 +4.5%
Operating Income	106.9 12.3%	101.8 11.0%	(5.1) (4.8%)	26.3 +24.6%	330.2 10.3%	Record high 350.2 10.4%	20.1 +6.1%	57.4 +17.4%
Income before Income Taxes	103.4 11.9%	Record high 104.4 11.3%	1.0 +1.0%		340.6 10.7%	Record high 366.6 10.9%	26.0 +7.6%	
Net Income Attributable to FUJIFILM Holdings	79.4 9.1%	Record high 83.4 9.0%	3.9 +5.0%		261.0 8.2%	Record high 276.7 8.2%	15.8 +6.0%	
EPS	¥65.92	¥69.17	¥3.25		¥216.67	¥229.65	¥12.98	
ROE	-	-	-		8.0%	7.7%	(0.3 pt)	
ROIC	-	-	-		5.9%	5.5%	(0.4 pt)	
CCC	-	-	-		95 days	106 days	11 days	
Exchange Rates ¥/US$	¥152	¥157	¥5		¥152	¥151	(¥1)	
Exchange Rates ¥/€	¥161	¥184	¥23		¥164	¥175	¥11	

FY2025 (Fiscal Year Ended March 2026)

Consolidated Revenue and Operating Income by Operating Segment

(Billions of yen)

Revenue	Q4						Full Year					
	FY2024	FY2025	Change		Constant-currency basis		FY2024	FY2025	Change		Constant-currency basis	
* Healthcare	316.5	333.6	17.2	+5.4%	6.5	+2.1%	1,047.8	1,098.9	51.2	+4.9%	42.7	+4.1%
* Electronics	100.1	127.5	27.4	+27.4%	23.9	+23.9%	407.6	456.2	48.6	+11.9%	48.3	+11.8%
Business Innovation	336.4	324.8	(11.7)	(3.5%)	(20.3)	(6.0%)	1,198.5	1,174.8	(23.7)	(2.0%)	(26.0)	(2.2%)
Imaging	115.3	141.4	26.1	+22.6%	16.6	+14.4%	542.0	627.1	85.1	+15.7%	79.2	+14.6%
Total	868.3	927.3	58.9	+6.8%	26.8	+3.1%	3,195.8	3,357.0	161.1	+5.0%	144.2	+4.5%

Operating Income	Q4						Full Year					
	FY2024	FY2025	Change		Excluding FX, one-time cost and raw material impacts		FY2024	FY2025	Change		Excluding FX, one-time cost and raw material impacts	
* Healthcare	45.4	29.7	(15.7)	(34.7%)	7.1	+15.6%	79.9	63.6	(16.2)	(20.3%)	7.3	+9.1%
* Electronics	17.6	30.7	13.0	+74.0%	12.2	+69.2%	75.1	100.9	25.8	+34.4%	26.0	+34.6%
Business Innovation	31.9	27.0	(4.9)	(15.4%)	2.1	+6.6%	74.6	63.7	(10.9)	(14.6%)	(2.7)	(3.6%)
Imaging	24.2	24.5	0.3	+1.1%	2.7	+11.2%	139.2	160.0	20.8	+14.9%	26.1	+18.7%
Corporate Expenses & Eliminations	(12.2)	(10.0)	2.2		2.2		(38.6)	(38.0)	0.6		0.6	
Total	106.9	101.8	(5.1)	(4.8%)	26.3	+24.6%	330.2	350.2	20.1	+6.1%	57.4	+17.4%

* The Chemical Reagent business has been reclassified from the Electronics (AF Materials) segment to the Healthcare (LS Solutions) segment.
The information for FY2024 has been restated in line with the above change in the segmentation.

Q4 FY2025 (January to March 2026)


Business Summary: Healthcare

Revenue and income

(Billions of yen)

	FY2024	FY2025	Change		Excluding FX, one-time cost and raw material impacts
Revenue	316.5	**333.6**	17.2	+5.4%	+2.1%
Medical Systems	206.1	217.1	11.0	+5.4%	+2.4%
Bio CDMO	73.0	73.9	0.9	+1.2%	(4.1%)
LS Solutions	37.4	42.6	5.2	+14.0%	+12.5%
Operating Income	45.4	**29.7**	(15.7)	(34.7%)	+15.6%
Operating Margin	14.3%	**8.9%**	(5.4pt)		

Operating income analysis



Factors affecting revenue

Medical Systems

+ Sales of endoscope increased in the U.S. and Europe, as well as in Japan and China. Driven in part by a concentration of deliveries for large-scale orders, sales grew by approximately 30% YoY
+ Strong sales of CT, MRI and IVD

Bio CDMO *Profitability: refer to p31

+ Revenue increased by just under 40%, driven by the expansion of operations at new large-scale Bio CDMO facilities
− Revenue from small-to medium scale facilities declined due to absence of cancellation fees recorded in the previous fiscal year and delays in securing early-stage projects

LS Solutions

+ Sales of culture media increased, driven by expanded usage by major pharmaceutical companies
+ Strong sales of reagents reflecting a recovery in market conditions

Main factors affecting income

One-time factor (Q4 FY2024)

Sale of assets and others

Operations

+ Medical Systems / LS Solutions — Increased gross margin driven by revenue growth
− Bio CDMO — Upfront costs associated with the start of operations of new large-scale Bio CDMO facilities (U.S.)

Raw materials prices

Medical Systems — Rising silver prices, etc.

One-time factor (Q4 FY2025)

Bio CDMO — Optimization of production structure for small-to medium-scale facilities, etc.

Q4 FY2025 (January to March 2026)

Business Summary: Electronics

Revenue and income

(Billions of yen)

	FY2024	FY2025	Change		Excluding FX, one-time cost and raw material impacts
Revenue	100.1	**127.5**	27.4	+27.4%	+23.9%
Semiconductor Materials	63.2	81.7	18.5	+29.3%	+24.4%
AF Materials	36.9	45.8	8.9	+24.1%	+23.0%
Operating Income	17.6	**30.7**	13.0	+74.0%	+69.2%
Operating Margin	17.6%	**24.1%**	+5.8pt		

Factors affecting revenue


■ **Semiconductor Materials**

+ Strong sales driven by capturing demand for AI semiconductors
  Sales of CMP slurries increased significantly
  Strong sales of liquid-type polyimides for advanced packaging
+ In addition to strong sales to major foundries, sales to major semiconductor manufacturers in the U.S. and South Korea recovered

■ **AF Materials**

+ Display materials: Strong sales of new materials and OLED materials
+ Data tape: Higher sales to major IT companies

Operating income analysis



Main factors affecting income affecting income

■ **One-time factor (Q4 FY2024)**

Sale of assets and others

■ **Operations**

Higher gross margin driven by increased sales of Semiconductor Materials

■ **One-time factor (Q4 FY2025)**

+ Sale of assets and others

Q4 FY2025 (January to March 2026)

Business Summary: Business Innovation

Revenue and income

(Billions of yen)

	FY2024	FY2025	Change		Excluding FX, one-time cost and raw material impacts
Revenue	336.4	**324.8**	(11.7)	(3.5%)	(6.0%)
Business Solutions	101.1	108.0	6.9	+6.8%	+4.6%
Office Solutions	143.8	125.9	(17.9)	(12.5%)	(14.5%)
Graphic Communications	91.6	90.9	(0.6)	(0.7%)	(4.4%)
Operating Income	31.9	**27.0**	(4.9)	(15.4%)	+6.6%
Operating Margin	9.5%	8.3%	(1.2pt)		

Factors affecting revenue

■ **Business Solutions (BS)**

+ Higher revenue from DX solutions
+ Higher revenue from services provided to municipalities in Japan


■ **Office Solutions (OS)**

− Sluggish market conditions in the AP region and the reduction of low-margin models
− A decline in exports to Europe and the U.S.

■ **Graphic Communications (GC)**

+ Higher revenue from xerographic machines in new markets
− Lower demand for printing plates and related products amid sluggish market conditions in Europe

Operating income analysis



Main factors affecting income

■ **One-time factor (Q4 FY2024)**

GC Structure strengthening expenses, etc.
Common Sale of assets

■ **Operations**

BS Increase in gross margin, driven by higher revenue, etc.
Common Initial and related costs incurred in connection with the ERP system renewal

■ **One-time factor (Q4 FY2025)**

BS/OS/GC Structure strengthening expenses, etc.

Q4 FY2025 (January to March 2026)

Business Summary: Imaging

Revenue and income

(Billions of yen)

	FY2024	FY2025	Change		Excluding FX, one-time cost and raw material impacts
Revenue	115.3	**141.4**	26.1	+22.6%	+14.4%
Consumer Imaging	65.2	82.2	17.1	+26.2%	+17.6%
Professional Imaging	50.1	59.1	9.0	+18.0%	+10.2%
Operating Income	24.2	**24.5**	0.3	+1.1%	+11.2%
Operating Margin	21.0%	**17.3%**	(3.7pt)		

Factors affecting revenue


■ **Consumer Imaging**

+ Sales of *instax* instant photo systems, including the mainstay models *instax mini 12* and *instax mini Evo*, as well as *instax WIDE 400* and *instax Link 3*, remained strong across a broad range of user segments
+ Supply increased following enhancements in *instax* film production facilities

■ **Professional Imaging**

+ Sales of *FUJIFILM X* and *GFX* series digital cameras, including the new *X-T30 III*, remained strong

Operating income analysis



Main factors affecting income

■ **One-time factor (Q4 FY2024)**

Sale of assets and others

■ **Operations**


Higher gross margin driven by higher revenue from instant photo systems and digital cameras

■ **Raw materials**

Rising silver prices, etc.

FY2025 (April 2025 to March 2026)

Consolidated Cash Flow



(Billions of yen)

	FY2023	FY2024	FY2025
Net income	**243.3**	**261.7**	**277.3**
Depreciation & amortization	150.0	163.6	**172.4**
Change in notes and accounts receivable / others	(5.8)	34.4	**(31.4)**
Change in inventories	62.0	(0.3)	**(23.9)**
Change in notes and accounts payable - trade / others	7.5	47.6	**(14.5)**
Change in working capital	63.7	81.7	**(69.7)**
Others	13.6	(11.7)	**59.8**
Cash-In	**470.6**	**495.2**	**439.7**
Capital expenditure	(422.1)	(532.1)	**(506.9)**
Purchases of software / rental assets	(66.3)	(75.0)	**(75.0)**
Acquisitions of businesses	(173.8)	(3.9)	**(6.1)**
Cash-Out	**(662.2)**	**(611.1)**	**(588.1)**
Adjusted free cash flows (FCF)	**(191.6)**	**(115.8)**	**(148.4)**
Adjusted free cash flows excluding business acquisitions*	**(17.8)**	**(112.0)**	**(142.3)**

*Business acquisitions are deducted from adjusted free cash flow.

FY2025 (April 2025 to March 2026)

Impact of the U.S. Tariff Policy

The impact of the U.S. tariff policy in FY2025 amounted to a negative ¥5.8 billion, mitigated by pricing measures and other initiatives

	4Q actual (3 months)	Full-year actual (12 months)	Full-year forecast (as of February 5, 2026)	Main products affected
Total	**-1.9 billion yen**	**-5.8 billion yen**	**-6.0 billion yen (approx. -$40M)**	
Healthcare	-1.3billion yen	-4.4billion yen	-4.0billion yen	Medical equipment
Electronics	-0.4billion yen	-0.9billion yen	-1.0billion yen	Semiconductor materials
Business Innovation	-0.2billion yen	-0.5billion yen	-1.0billion yen	Printing plates materials, inkjet printheads
Imaging	-	-	-	Instant photo systems, digital cameras

Financial Forecast for FY2026

03

* From Q2 FY2024, the amounts shown for each item in this document have been rounded off to the nearest ¥100million. As a result, there may be some discrepancies from figures published in the past, and in some cases there may be differences between the breakdown and the total. Percentages are based on the actual amount.

Full-year Forecast for FY2026

Aiming to achieve record highs for revenue, operating income and net income attributable to FUJIFILM Holdings by implementing pricing measures and other initiatives to offset the rising raw materials costs, including semiconductor memory and silver

(Billions of yen)

	FY2025 Actual	FY2026 forecast	Change from FY2025
Revenue	3,357.0 100.0%	Record high **3,470.0** **100.0%**	113.0 +3.4%
Operating Income	350.2 10.4%	Record high **365.0** **10.5%**	14.8 +4.2%
Income before Income Taxes	366.6 10.9%	Record high **375.0** **10.8%**	8.4 +2.3%
Net Income Attributable to FUJIFILM Holdings	276.7 8.2%	Record high **280.0** **8.1%**	3.3 +1.2%
EPS	¥229.65	* **¥234.19**	¥4.54
ROE	7.7%	**7.8%**	0.1 pt
ROIC	5.5%	**5.6%**	0.1 pt
CCC	106 days	**101 days**	(5 days)
Exchange Rates ¥/US$	¥151	**¥150**	(¥1)
¥/€	¥175	**¥175**	-
Silver Price (/kg)	¥247,000	**¥400,000**	¥153,000

* The weighted average number of shares outstanding used as the basis for calculating EPS (net income attributable to FUJIFILM Holding per share) is calculated by deducting the number of shares repurchased by April 30, 2026 pursuant to the resolution of the Board of Directors held on March 30, 2026 from the number of issued shares outstanding (excluding treasury stock) as of March 31, 2026.

Financial Forecast by Operating Segment

- **Revenue is projected to reach ¥3,470.0 billion, driven by the expansion of operations at new Bio CDMO facilities and increased sales of Semiconductor Materials**
- **Operating income is expected to reach ¥365.0 billion, with profit increases anticipated across all segments**

(Billions of yen)

Revenue	FY2025 Actual	FY2026 forecast	Change from FY2025		Constant-currency basis	
Healthcare	1,098.9	**1,170.0**	71.1	+6.5%	73.6	+6.7%
Electronics	456.2	**475.0**	18.8	+4.1%	20.3	+4.5%
Business Innovation	1,174.8	**1,175.0**	0.2	+0.0%	1.2	+0.1%
Imaging	627.1	**650.0**	22.9	+3.7%	23.9	+3.8%
Total	3,357.0	**3,470.0**	113.0	+3.4%	119.0	+3.5%

Operating Income	FY2025 Actual	FY2026 forecast	Change from FY2025		Excluding FX, one-time cost and raw material impacts	
Healthcare	63.6	**69.0**	5.4	+8.4%	8.4	+13.2%
Electronics	100.9	**106.0**	5.1	+5.1%	7.9	+7.8%
Business Innovation	63.7	**65.0**	1.3	+2.0%	0.2	+0.3%
Imaging	160.0	**162.0**	2.0	+1.2%	13.5	+8.4%
Corporate Expenses & Eliminations	(38.0)	**(37.0)**	1.0	-	1.0	-
Total	350.2	**365.0**	14.8	+4.2%	31.0	+8.9%

Impact of Rising Semiconductor Memory Prices and the Situation in the Middle East

- **For rising semiconductor memory prices, the Company is mitigating the negative impact on business performance mainly through pricing measures and sourcing of alternative products. Most of the required volume for the current fiscal year has already been secured**
- **Regarding the escalating instability in the Middle East, although higher energy prices, rising costs for related raw materials and packaging materials, and tight supply-demand conditions are expected, these potential impacts have not been factored into the financial forecast for FY2026 due to significant uncertainty surrounding the outlook**

Risks	Measures	Impact on operating income for FY2026 (before implementing measures)
Rising semiconductor memory prices	**Pricing measures, sourcing alternatives, etc.** * Most of the required volume for FY2026 is already secured	**-¥11.0 billion/year (factored into the financial forecast)**
Impact of situation in the Middle East*1		**If the current situation were to continue through the end of the Q1: -¥3.0 billion to -4.0 billion/quarter*2 (not factored into the financial forecast)**
(1) Rising energy prices	Pricing measures (as a general principle)	
(2) Rising crude oil-derived raw materials and packaging prices	Pricing measures, cost reductions initiativesm etc.	
(3) Tight supply-demand due to (1) and (2)	Sourcing alternatives, diversifying suppliers, etc.	

*1 The impact on direct sales in the Middle East region is negligible and is not factored into the financial forecast
*2 Crude oil price assumption: USD 100/bbl

ROIC (Return on Invested Capital)

- **In FY2025, ROIC came in at 5.5%, down 0.4 percentage points YoY, reflecting continued growth investments in the Healthcare segment and delays in profitability improvement**
- **For FY2026, while continuing growth investments in Bio CDMO and Semiconductor Materials businesses, the Company plans ROIC of 5.6%, up 0.1 percentage points YoY, driven by company-wide improvements in profitability**

ROIC forecast by segment


	FY2024 Actual	FY2025 Actual	FY2026 Forecast	Change from FY2025
Healthcare	2.5%	1.6%	1.8%	+0.2pt
Electronics	12.1%	15.0%	15.8%	+0.8pt
Business Innovation	5.4%	4.4%	4.8%	+0.4pt
Imaging	54.8%	51.3%	51.1%	(0.2pt)
*Segment ROIC = NOPAT/(working capital + fixed assets)				
Total	**5.9%**	**5.5%**	**5.6%**	**+0.1pt**

*Company-wide ROIC = NOPAT/(interest-bearing debt + shareholders' equity)

* The chemical reagent business has been reclassified from the Electronics (AF Materials) segment to the Healthcare (LS Solutions) segment. The information for FY2024 has been restated in line with the above change in the segmentation.

Cash Allocation (FY2026 Forecast)

- **Free cash flow is expected to turn positive in FY2026 as capital expenditures in Bio CDMO decrease significantly**
- **The Company will focus on capital efficiency, continuing to allocate funds toward growth investments, primarily in Bio CDMO and Semiconductor Materials, while also emphasizing shareholder returns**



Implement Management That Is Conscious of Cost of Capital and Stock Price

Aiming to achieve an ROE of 10% or higher in FY2030 by continuously improving ROIC across all business segments and ensuring appropriate capital allocation, while contributing to the sustainable enhancement of stock price (PBR)

Initiatives to improve ROIC

(1) Improve profitability

- Overall operating margin for FY2025 was 10.4% (up 0.1 percentage points YoY)
- Start of operations at the new Bio CDMO facilities in the U.S.
- Implementation of pricing measures to offset additional U.S. tariffs and the rising raw material costs, including silver
- Withdrawal from low-profit products and implementation of structural reinforcement measures for low-profitability businesses

(2) Optimization of non-core assets


- Divestiture of the medical media business of LS Solutions (April 2025)
- Reduction of cross-shareholdings
- Reduction of real estate holdings (including buildings and land)


(3) Improve CCC

- Continued efforts to improve working capital efficiency (from 116 days in FY2023 to 106 days in FY2025)

(4) Share buyback

- Execution of a share buyback (of up to ¥30.0 billion) following a comprehensive assessment of the increased likelihood of generating positive free cash flow in FY2026 and current stock price levels in light of mid-to-long-term earnings growth






Shareholder Returns

Dividend trends (forecast)

Annual dividend for FY2025 : ¥70.0 per share
Annual dividend for FY2026 : ¥75.0 per share



Policy on shareholder returns

1. Ensure a **balance** between business growth and financial discipline
2. Provide **stable and continuous dividends** with returns to shareholders through **dividends** as our basic policy
3. Target a dividend payout ratio of **30%**
4. Consider and implement share buybacks **based on trends in cash flow, share price and other factors**

Appendices:
Financial Results for FY2025

04

* From Q2 FY2024, the amounts shown for each item in this document have been rounded off to the nearest ¥100 million. As a result, there may be some discrepancies from figures published in the past, and in some cases there may be differences between the breakdown and the total. Percentages are based on the actual amount.

Q4 / Full-year Earnings

(Billions of yen)

	Revenue	Q4 FY2024	Q4 FY2025	Q4 Change		Q4 Constant-currency basis		Full Year FY2024	Full Year FY2025	Full Year Change		Full Year Constant-currency basis	
*	**Healthcare**	**316.5**	**333.6**	**17.2**	**+5.4%**	**6.5**	**+2.1%**	**1,047.8**	**1,098.9**	**51.2**	**+4.9%**	**42.7**	**+4.1%**
	Medical Systems	206.1	217.1	11.0	+5.4%	4.9	+2.4%	693.2	701.6	8.3	+1.2%	5.4	+0.8%
	Bio CDMO	73.0	73.9	0.9	+1.2%	(3.0)	(4.1%)	219.5	254.1	34.6	+15.8%	29.0	+13.2%
	LS Solutions	37.4	42.6	5.2	+14.0%	4.7	+12.5%	135.0	143.2	8.2	+6.1%	8.3	+6.2%
*	**Electronics**	**100.1**	**127.5**	**27.4**	**+27.4%**	**23.9**	**+23.9%**	**407.6**	**456.2**	**48.6**	**+11.9%**	**48.3**	**+11.8%**
	Semiconductor Materials	63.2	81.7	18.5	+29.3%	15.4	+24.4%	250.4	294.6	44.1	+17.6%	43.7	+17.4%
	AF Materials	36.9	45.8	8.9	+24.1%	8.5	+23.0%	157.2	161.6	4.4	+2.8%	4.6	+2.9%
	Business Innovation	**336.4**	**324.8**	**(11.7)**	**(3.5%)**	**(20.3)**	**(6.0%)**	**1,198.5**	**1,174.8**	**(23.7)**	**(2.0%)**	**(26.0)**	**(2.2%)**
	Business Solutions	101.1	108.0	6.9	+6.8%	4.6	+4.6%	330.9	356.8	25.9	+7.8%	25.5	+7.7%
	Office Solutions	143.8	125.9	(17.9)	(12.5%)	(20.9)	(14.5%)	522.9	482.7	(40.2)	(7.7%)	(40.6)	(7.8%)
	Graphic Communications	91.6	90.9	(0.6)	(0.7%)	(4.0)	(4.4%)	344.7	335.3	(9.4)	(2.7%)	(10.9)	(3.2%)
	Imaging	**115.3**	**141.4**	**26.1**	**+22.6%**	**16.6**	**+14.4%**	**542.0**	**627.1**	**85.1**	**+15.7%**	**79.2**	**+14.6%**
	Consumer Imaging	65.2	82.2	17.1	+26.2%	11.5	+17.6%	328.0	367.9	39.9	+12.2%	35.8	+10.9%
	Professional Imaging	50.1	59.1	9.0	+18.0%	5.1	+10.2%	214.0	259.2	45.2	+21.1%	43.4	+20.3%
	Total	868.3	927.3	58.9	+6.8%	26.8	+3.1%	3,195.8	3,357.0	161.1	+5.0%	144.2	+4.5%

(Billions of yen)

	Operating Income [Operating Margin]	Q4 FY2024	Q4 FY2025	Q4 Change		Q4 Excluding FX, one-time cost and raw material impacts		Full Year FY2024	Full Year FY2025	Full Year Change		Full Year Excluding FX, one-time cost and raw material impacts	
*	Healthcare	45.4	29.7	(15.7)	(34.7%)	7.1	+15.6%	79.9	63.6	(16.2)	(20.3%)	7.3	+9.1%
		[14.3%]	[8.9%]					[7.6%]	[5.8%]				
*	Electronics	17.6	30.7	13.0	+74.0%	12.2	+69.2%	75.1	100.9	25.8	+34.4%	26.0	+34.6%
		[17.6%]	[24.1%]					[18.4%]	[22.1%]				
	Business Innovation	31.9	27.0	(4.9)	(15.4%)	2.1	+6.6%	74.6	63.7	(10.9)	(14.6%)	(2.7)	(3.6%)
		[9.5%]	[8.3%]					[6.2%]	[5.4%]				
	Imaging	24.2	24.5	0.3	+1.1%	2.7	+11.2%	139.2	160.0	20.8	+14.9%	26.1	+18.7%
		[21.0%]	[17.3%]					[25.7%]	[25.5%]				
	Corporate Expenses & Eliminations	(12.2)	(10.0)	2.2		2.2		(38.6)	(38.0)	0.6		0.6	
	Total	106.9	101.8	(5.1)	-4.8%	26.3	+24.6%	330.2	350.2	20.1	+6.1%	57.4	+17.4%
		[12.3%]	[11.0%]					[10.3%]	[10.4%]				

* The chemical reagent business has been reclassified from the Electronics segment (AF Materials) to the Healthcare segment (LS Solutions). The information for FY2024 has been restated in line with the above change in the segmentation.

Quarterly Earnings

(Billions of yen)

	Revenue	FY2024 Q1	FY2024 Q2	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4
*	**Healthcare**	**235.2**	**249.0**	**247.1**	**316.5**	**228.5**	**270.7**	**266.1**	**333.6**
	Medical Systems	157.7	166.9	162.6	206.1	144.0	170.3	170.2	217.1
	Bio CDMO	47.1	48.1	51.3	73.0	53.2	66.3	60.8	73.9
	LS Solutions	30.4	34.1	33.2	37.4	31.3	34.1	35.2	42.6
*	**Electronics**	**103.1**	**102.5**	**101.9**	**100.1**	**102.1**	**107.3**	**119.2**	**127.5**
	Semiconductor Materials	62.3	63.0	61.9	63.2	64.7	70.6	77.7	81.7
	AF Materials	40.8	39.5	40.0	36.9	37.5	36.8	41.5	45.8
	Business Innovation	**280.0**	**287.7**	**294.4**	**336.4**	**273.6**	**298.6**	**277.8**	**324.8**
	Business Solutions	70.8	81.1	77.9	101.1	75.8	92.3	80.8	108.0
	Office Solutions	126.8	121.8	130.5	143.8	120.0	121.2	115.7	125.9
	Graphic Communications	82.5	84.8	85.9	91.6	77.8	85.2	81.4	90.9
	Imaging	**130.7**	**126.5**	**169.5**	**115.3**	**145.3**	**146.2**	**194.2**	**141.4**
	Consumer Imaging	74.6	77.6	110.6	65.2	77.3	85.3	123.0	82.2
	Professional Imaging	56.1	48.9	58.9	50.1	68.0	60.9	71.2	59.1
	Total	749.0	765.7	812.8	868.3	749.5	822.9	857.4	927.3

(Billions of yen)

	Operating Income	FY2024 Q1	FY2024 Q2	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4
*	Healthcare	3.5	19.5	11.4	45.4	4.3	19.4	10.3	29.7
*	Electronics	19.9	18.8	18.7	17.6	22.5	19.4	28.2	30.7
	Business Innovation	14.4	10.8	17.5	31.9	15.6	15.8	5.4	27.0
	Imaging	32.5	33.7	48.8	24.2	41.8	38.6	55.1	24.5
	Corporate Expenses & Eliminations	(8.2)	(9.4)	(8.7)	(12.2)	(8.8)	(10.0)	(9.1)	(10.0)
	Total	62.2	73.4	87.7	106.9	75.3	83.2	90.0	101.8
	Exchange Rates ¥/US$	¥156	¥149	¥152	¥152	¥145	¥148	¥154	¥157
	¥/€	¥168	¥164	¥163	¥161	¥164	¥172	¥179	¥184

* The chemical reagent business has been reclassified from the Electronics segment (AF Materials) to the Healthcare segment (LS Solutions). The information for FY2024 has been restated in line with the above change in the segmentation.

Consolidated Revenue by Geographical Area

(Billions of yen)

	FY2024 Full Year		FY2025 Full Year		Change	
	Ratio (%)		Ratio (%)			
Japan	34.4%	1,099.3	**34.8%**	**1,168.7**	69.4	+6.3%
The Americas	20.2%	646.9	**19.6%**	**657.9**	11.0	+1.7%
Europe	17.0%	544.6	**17.3%**	**581.1**	36.5	+6.7%
China	14.3%	455.5	**14.8%**	**497.7**	42.2	+9.3%
Asia and others	28.3%	905.0	**28.3%**	**949.3**	44.3	+4.9%
Overseas	65.6%	2,096.5	**65.2%**	**2,188.3**	91.8	+4.4%
Consolidated total	100.0%	3,195.8	**100.0%**	**3,357.0**	161.1	+5.0%

Operating Income Analysis (Q4 YoY)

(Billions of yen)

		Q4											
		FY2024 Actual	FY2025 Actual	Change	Operation and others	FX	Raw Material price	Tariff Impact	(b-a) One-time cost	(a) FY2024 Q4	(b) FY2025 Q4	Business	Detail
*1	Healthcare	45.4	29.7	(15.7)	7.1	0.2	(6.2)	(1.3)	(15.5)	11.0	(4.5)		
									1.5	(1.5)	-	Medical	FHC*2 domestic sales division integration costs
									(5.5)	-	(5.5)	CDMO	Optimization of the production structure of small- to medium-scale facilities
									1.0	(1.0)	-	LS solutions	Business divestiture costs
									(12.5)	13.5	1.0	Others	Sale of non-core assets / Others
*1	Electronics	17.6	30.7	13.0	12.2	1.3	(0.6)	(0.4)	0.6	2.2	2.8		
									0.8	(0.8)	-	Semiconductor	Acquisition
									0.2	(1.4)	(1.2)	AF	Structure strengthening expenses/ Others
									(0.4)	4.4	4.0	Others	Sale of non-core assets / Others
	Business Innovation	31.9	27.0	(4.9)	2.1	1.5	(0.7)	(0.2)	(7.5)	1.7	(5.8)		
									(2.0)	(0.6)	(2.6)	Graphic	Structure strengthening expenses/ Others
									0.7	(0.7)	-	Graphic	Disputed cost / Others
									(3.6)		(3.6)	Offfice Solutions and Others	Structure strengthening expenses/ Others
									(2.6)	3.0	0.4	Offfice Solutions and Others	Sale of non-core assets / Others
	Imaging	24.2	24.5	0.3	2.7	3.6	(2.5)	-	(3.5)	4.1	0.6		
									0.6	(0.6)	-	Imaging	Structure strengthening expenses / Others
									(4.1)	4.7	0.6	Imaging	Sale of non-core assets / Others
	Corporate Expenses & Eliminations	(12.2)	(10.0)	2.2	2.2	-	-	-	-	-	-		
	Total	106.9	101.8	(5.1)	26.3	6.4	(10.0)	(1.9)	(25.9)	19.0	(6.9)		

Exchange Rates				
	USD	¥152	¥157	¥5
	EUR	¥161	¥184	¥23

Silver	(9.5)
Aluminum	(0.8)
Others (fuel etc)	0.3

*1 The chemical reagent business has been reclassified from the Electronics segment (AF Materials) to the Healthcare segment (LS Solutions). The information for FY2024 has been restated in line with the above change in the segmentation.
*2 FUJIFILM Healthcare Corporation

Operating Income Analysis (Q4 Actual vs. Previous Forecast)

(Billions of yen)

	Q4											
	FY2025 Forecast	FY2025 Actual	Change	Operation and others	FX	Raw Material price	tariff	(b-a) One-time cost	(a) Previous forecast	(b) Actual	Business	Detail
Healthcare	33.0	29.7	(3.4)	(2.6)	0.1	-	(0.4)	(0.5)	(4.0)	(4.5)		
								(1.5)	(4.0)	(5.5)	CDMO	Optimization of the production structure of small- to medium-scale facilities
								1.0	-	1.0	Others	Sale of non-core assets / Others
Electronics	24.8	30.7	5.9	2.3	0.7	-	0.1	2.8	-	2.8		
								(1.2)	-	(1.2)	AF	Structure strengthening expenses/ Others
								4.0	-	4.0	Others	Sale of non-core assets / Others
Business Innovation	27.2	27.0	(0.3)	(2.9)	0.7	-	0.5	1.4	(7.2)	(5.8)		
								0.2	(2.8)	(2.6)	Graphic	Structure strengthening expenses/ Others
								0.8	(0.8)	-	Graphic	Disputed cost / Others
								-	(3.6)	(3.6)	Office Solutions and Others	Structure strengthening expenses/ Others
								0.4	-	0.4	Office Solutions and Others	Sale of non-core assets / Others
Imaging	11.5	24.5	13.0	9.9	2.5	-	-	0.6	-	0.6		
								0.6	-	0.6	Imaging	Sale of non-core assets / Others
Corporate Expenses & Eliminations	(10.0)	(10.0)	-	0.1	(0.1)	-	-	-	-	-		-
Total	86.5	101.8	15.2	6.8	3.9	-	0.2	4.3	(11.2)	(6.9)		

Exchange Rates				
	USD	¥155	¥157	¥2
	EUR	¥175	¥184	¥9

Silver	-
Aluminum	-
Others (fuel etc)	-

Bio CDMO Profitability (Q4 YoY)

(Billions of yen)

Bio CDMO	Q4			Full Year		
	FY2024	FY2025	vs Previous Year	FY2024	FY2025	vs Previous Year
Revenue	73.0	**73.9**	0.9	219.5	**254.1**	34.6
Scheduled maintenance at Denmark facilities					**(10.0)**	(10.0)
Optimization of the production structure		**(5.5)**	(5.5)	(5.0)	**(6.5)**	(1.5)
Reinforcing the commercial production in Texas				(13.0)		13.0
Total one-time costs		**(5.5)**	(5.5)	(18.0)	**(16.5)**	1.5
EBITDA Margin (excludes one-time costs)	Low-Teens %	**Low-Teens %**	-	Low-teens %	**Approx. 10%**	-
Large scale facilities	High 20s %	**High-Teens %**	-	High 20s %	**Mid 20s %**	-
Small- to medium-scale facilities	Low single digit %	**Mid-single digit %**	-	Breakeven	**Negative 10%**	-

Full-year Forecast for FY2026

Revenue by Business

(Billions of yen)

		FY2025 Actual	FY2026 Forecast	Change from previous year: Amount of money	Change from previous year: With currency impact	Change from previous year: Constant currency basis
	Healthcare	**1,098.9**	**1,170.0**	**71.1**	**+6.5%**	**+6.7%**
	Medical Systems	701.6	720.0	18.4	+2.6%	
*	Bio CDMO	257.2	300.0	42.8	+16.7%	
*	LS Solutions	140.2	150.0	9.8	+7.0%	
	Electronics	**456.2**	**475.0**	**18.8**	**+4.1%**	**+4.5%**
	Semiconductor Materials	294.6	310.0	15.4	+5.2%	
	AF Materials	161.6	165.0	3.4	+2.1%	
	Business Innovation	**1,174.8**	**1,175.0**	**0.2**	**+0.0%**	**+0.1%**
	Business Solutions	356.8	380.0	23.2	+6.5%	
	Office Solutions	482.7	480.0	(2.7)	(0.6%)	
	Graphic Communications	335.3	315.0	(20.3)	(6.0%)	
	Imaging	**627.1**	**650.0**	**22.9**	**+3.7%**	**+3.8%**
	Consumer Imaging	367.9	375.0	7.1	+1.9%	
	Professional Imaging	259.2	275.0	15.8	+6.1%	
	Total	**3,357.0**	**3,470.0**	**113.0**	**+3.4%**	**+3.5%**
	Exchange Rates					
	¥/US$	¥151	¥150	(¥1)		
	¥/€	¥175	¥175	-		

* Business related to process development and contract manufacturing of cell therapy using iPS cells have been reclassified from the LS Solutions business within the Healthcare segment to the Bio CDMO business. The information for FY2025 has been restated in line with the above change in the segmentation.

Operating Income Analysis (FY2026 Forecast vs FY2025 Actual)

(Billions of yen)

	FY2025 Actual	FY2026 Forecast	Change	Operation and others	FX	Raw Material price	(b-a) One-time cost	(a) FY2025 Actual	(b) FY2026 Forecast	Business	Detail
Healthcare	63.6	**69.0**	5.4	8.4	(0.5)	(24.0)	21.5	(15.5)	**6.0**		
							6.5	(6.5)	-	CDMO	Optimization of the production structure of small- to medium-scale
							10.0	(10.0)	-	CDMO	Scheduled maintenance at Denmark facilities
							5.0	1.0	**6.0**	Others	Sale of non-core assets / Others
Electronics	100.9	**106.0**	5.1	7.9	(0.5)	-	(2.3)	2.8	**0.5**		
							0.2	(1.2)	**(1.0)**	AF	Structure strengthening expenses/ Others
							(2.5)	4.0	**1.5**	Others	Sale of non-core assets / Others
Business Innovation	63.7	**65.0**	1.3	0.2	-	(2.0)	3.1	(10.1)	**(7.0)**		
							(8.2)	(2.8)	**(11.0)**	Graphic	Structure strengthening expenses / Others
							(0.8)	(1.7)	**(2.5)**	Graphic	Disputed cost / Others
							(4.5)	(5.0)	**(9.5)**	Office Solutions and Others	Structure strengthening expenses / Others
							1.0	(1.0)	-	Office Solutions and Others	Disposal of unutilized assets / Others
							15.6	0.4	**16.0**	Office Solutions and Others	Sale of non-core assets / Others
Imaging	160.0	**162.0**	2.0	13.5	-	(10.0)	(1.5)	-	**(1.5)**		
							(4.4)	(0.6)	**(5.0)**	Imaging	Structure strengthening expenses / Others
							2.9	0.6	**3.5**	Others	Sale of non-core assets / Others
Corporate Expenses & Eliminations	(38.0)	**(37.0)**	1.0	1.0	-	-	-	-	-	-	
Total	350.2	**365.0**	14.8	31.0	(1.0)	(36.0)	20.8	(22.8)	**(2.0)**		

Exchange Rates				
	USD	¥151	**¥150**	(¥1)
	EUR	¥175	**¥175**	-

Silver	(25.0)
Aluminum	-
Others(fuel etc)	-
memory semiconductor	(11.0)

FY2025 (Fiscal Year Ended March 2026)

Consolidated Balance Sheets

(Billions of yen)


	Mar. 2024	Mar. 2025	Mar. 2026	Change from Mar. 2025
Cash and cash equivalents	179.7	172.1	**170.6**	(1.6)
Notes and accounts receivable	696.6	700.0	**762.5**	62.5
Inventories	547.8	544.0	**600.8**	56.8
Other current assets	150.5	165.6	**185.2**	19.6
Total current assets	**1,574.6**	**1,581.7**	**1,719.0**	**137.4**
Property, plant and equipment	1,395.7	1,786.5	**2,308.3**	521.8
Goodwill, net	953.8	947.9	**997.1**	49.1
Other noncurrent assets	859.3	933.8	**1,029.3**	95.5
Total noncurrent assets	**3,208.8**	**3,668.2**	**4,334.7**	**666.5**
Total assets	**4,783.5**	**5,249.9**	**6,053.8**	**803.9**

	Mar. 2024	Mar. 2025	Mar. 2026	Change from Mar. 2025
Short-term and long-term debt	502.8	685.9	**894.9**	209.0
Notes and accounts payable	346.5	390.6	**389.8**	(0.7)
Other liabilities	760.8	820.7	**924.7**	104.0
Total liabilities	**1,610.1**	**1,897.2**	**2,209.4**	**312.2**
Total FUJIFILM Holdings shareholders' equity	3,169.2	3,348.5	**3,839.6**	491.1
Noncontrolling interests	4.1	4.2	**4.8**	0.6
Total equity	**3,173.3**	**3,352.7**	**3,844.4**	**491.7**
Total liabilities and equity	**4,783.5**	**5,249.9**	**6,053.8**	**803.9**

(yen)

Exchange Rates	Mar. 2024	Mar. 2025	Mar. 2026	Change from Mar. 2025
¥/US$	¥151	¥150	**¥160**	¥10
¥/€	¥163	¥162	**¥183**	¥21

Capital Expenditure and Depreciation & Amortization




(Billions of yen)

	Q4		Full Year		Forecast
	FY2024	FY2025	FY2024	FY2025	FY2026
Healthcare	101.4	99.0	449.2	426.3	230.0
Electronics	14.3	12.9	38.9	36.9	52.0
Business Innovation	8.8	8.7	25.9	25.4	29.0
Imaging	5.6	6.5	15.4	16.6	23.0
Corporate	1.5	0.9	2.6	1.8	4.0
Capex (Tangible fixed assets)	131.5	128.0	532.1	506.9	338.0
Healthcare	4.8	5.8	16.6	18.4	18.0
Electronics	0.5	0.4	1.3	1.6	2.0
Business Innovation	11.4	10.3	47.1	38.4	24.0
Imaging	1.7	5.2	6.2	12.4	15.0
Corporate	1.0	1.5	3.8	4.1	7.0
Capex (Software, rental equipment and others)	19.4	23.1	75.0	75.0	66.0
Healthcare	18.5	21.0	62.7	74.5	101.0
Electronics	7.3	8.4	28.7	30.7	34.0
Business Innovation	13.0	12.3	51.8	45.8	50.0
Imaging	6.1	5.4	17.4	17.2	21.0
Corporate	0.9	1.1	3.0	4.3	4.0
Depreciation & Amortization	45.7	48.2	163.6	172.4	210.0

* The chemical reagent business has been reclassified from the Electronics segment (AF Materials) to the Healthcare segment (LS Solutions).
The information for FY2024 has been restated in line with the above change in the segmentation.

R&D Expenses and SG&A Expenses



(Billions of yen)

	Q4		Full Year		Forecast
	FY2024	FY2025	FY2024	FY2025	FY2026
* Healthcare	15.9	12.6	61.3	53.3	
* Electronics	6.3	7.0	25.2	28.2	
Business Innovation	13.5	13.2	54.5	55.4	
Imaging	4.2	4.3	13.3	13.4	
Corporate	2.0	1.7	9.1	7.5	
R&D Expenses	41.9	38.8	163.4	157.8	172.0
<Ratio to revenue>	4.8%	4.2%	5.1%	4.7%	5.0%
SG&A Expenses	195.5	236.1	806.5	861.5	
<Ratio to revenue>	22.5%	25.5%	25.2%	25.7%	

* The chemical reagent business has been reclassified from the Electronics segment (AF Materials) to the Healthcare segment (LS Solutions).
The information for FY2024 has been restated in line with the above change in the segmentation.

Market Trend and Number of Employees

Exchange rates (average) / Raw material prices (average)

	Unit	FY2024 Q1	FY2024 Q2	FY2024 Q3	FY2024 Q4	FY2024 Full Year	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2025 Full Year
US$	¥US/$	156	149	152	152	152	145	148	154	157	151
€	¥/€	168	164	163	161	164	164	172	179	184	175
Silver	1,000/kg	143	144	155	155	148	155	184	249	440	247

Exchange rate sensitivity: Impact of 1 yen change (full year)

Last updated: Apr. 17, 2024

		Revenue	Operating Income
US$	per 1 yen	+5.0 billion yen	+1.0 billion yen
€	per 1 yen	+1.5 billion yen	+ 0.8 billion yen

Number of Employees

	Mar.2024	June 2024	Sep.2024	Dec.2024	Mar.2025	June 2025	Sep.2025	Dec.2025	Mar.2026
Consolidated total	72,254	72,929	72,989	72,901	72,593	74,534	74,205	73,975	73,526

References: Initiatives Toward Sustainability

New External Acknowledgement

Under the Fujifilm Group Purpose “Giving our world more smiles,” we will contribute further to the realization of a sustainable society by enhancing our initiatives to resolve social issues through business activities

■ **Sources of innovation that support our sustainable growth**

April 2026
DX
(Digital Transformation)

Highly evaluated for steady DX promotion, under a DX vision led by top management, by establishing an AI utilization platform across the entire company and a governance

DX銘柄2026
Digital Transformation

2 consecutive years, 6th time

March 2026
Intellectual Property
(Design Management)

23 products across a wide range of businesses were given the iF Design Award 2026

iF DESIGN AWARD 2026

iF Design Award 2026 logo
*iF Design Award

March 2026
Human Capital
(Health Management)

2026 健康経営銘柄
KENKO Investment for Health

6 consecutive years

2026 健康経営優良法人
KENKO Investment for Health
大規模法人部門
ホワイト500

10 consecutive years

Dec. 2025
Environment
(Climate Change and Water Resources)

Named in CDP’s “A-List” under the categories of climate change and water security

Climate Water CDP A List 2025

Climate Change: 4 consecutive years, 5th time
Water security: 6th time

Oct. 2025
Environment
(Supply Chain)

Received the highest Platinum award in an assessment by EcoVadis, an international sustainability rating agency

PLATINUM Top 1% ecovadis Sustainability Rating OCT 2025

4th time

* Including Proactive IT Management Stocks, the former DX Stocks

References

FUJIFILM Holdings - Investor Relations

https://ir.fujifilm.com/en/investors.html

FUJIFILM Holdings Integrated Report

https://ir.fujifilm.com/en/investors/ir-materials/integrated-report.html

IR Materials

https://ir.fujifilm.com/en/investors/ir-materials.html

Business Activities of the Fujifilm Group

https://ir.fujifilm.com/en/investors/ir-materials/business-overview.html


Fujifilm Group's Purpose
Giving our world more smiles
We bring diverse ideas, unique capabilities,
and extraordinary people together to change the world.
FUJIFILM
Value from Innovation

FUJIFILM

Value from Innovation